News

The nonprofit Autoimmune Registry (ARI) has published its first comprehensive list of autoimmune diseases, with information addressing more than 150 disorders, their subtypes, and prevalence in the U.S. This list was created in part to provide patients and scientists easy access to the latest peer-reviewed research, information on clinical…

Progressive multiple sclerosis (MS) is the focus of the 2020 virtual European Multiple Sclerosis Platform (EMSP) annual meeting that runs though Friday, Nov. 20. Registration is free for the two-day conference. Those interested in participating can register here. According to a EMSP press release, topics to be discussed include the most…

A software platform, called CogniSoft, allows for automated assessments of cognitive health in people with multiple sclerosis (MS). The platform was described in the study “CogniSoft: A Platform for the Automation of Cognitive Assessment and Rehabilitation of Multiple Sclerosis,” published in the journal Computers. Cognitive impairment…

Marked differences in disease characteristics are observed between male and female patients with multiple sclerosis (MS) but they are more pronounced when comparing patients across clinical subtypes, a new study finds. The analysis found that although women are more prone to…

Using a small molecule called TEPP-46 to block the non-metabolic function of the enzyme pyruvate kinase M2 (PKM2) in T-helper (Th) immune cells did not lessen disease severity and redirected inflammation and neural damage from the spinal cord to the brain in a mouse model of multiple sclerosis…

Scientists have created myelin-producing cells, called oligodendrocytes, from pluripotent stem cells derived from patients with multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS) in just three weeks. They also demonstrated these lab-made oligodendrocytes were able to produce myelin — the fatty substance that normally wraps around neurons’…

The U.K.’s MS Trust has been awarded £50,000 (about $65,800) from the Coronavirus Community Support Fund — distributed by The National Lottery Community Fund — to further its “Supporting the MS community during Covid-19” project. Expected to run for six months, the project aims…

Note: This story was updated Aug. 17, 2021, to note that T.gondii infection is a risk factor for rheumatoid arthritis and lupus, not a protective factor.  Toxoplasmosis, an infection by the parasite Toxoplasma gondii, may confer a certain level of protection against multiple sclerosis (MS), according…

Start2Cure Foundation is funding a research project that will investigate the potential of a gene therapy approach to treat multiple sclerosis (MS). MS is an autoimmune disease characterized by the damage and loss of myelin — the protective layer around nerve fibers, or axons, that is crucial to the…

A bone marrow transplant may be particularly useful for those with relapsing forms of multiple sclerosis (MS) who, despite treatment with high-efficacy disease-modifying therapies (DMTs), continue to experience relapses or show signs of new lesions, experts say. According to new recommendations from the National Multiple Sclerosis Society,…

The levels of the protein neurofilament light chain (NfL) in the blood when a person experiences a first demyelinating event associated with multiple sclerosis (MS) can predict brain atrophy up to a decade later, a new study shows. Titled “Association of Serum Neurofilament Light Levels…

A non-invasive retina imaging technique known as optical coherence tomography (OCT) provided evidence of the neuroprotective effect of ibudilast (MN-166) — an oral medication designed to reduce the body’s inflammatory responses —  in people with progressive forms of multiple sclerosis (MS). The data also…

Exposure to air pollution, particularly to particulate matter 10 (PM10), small airborne and inhalable particles, may trigger inflammatory reactions in people with multiple sclerosis (MS), an Italian study reported. The study “Air pollution as a contributor to the inflammatory activity of multiple sclerosis” was published in the Journal of…

Immunic Therapeutics is seeking 60 more adults with relapsing-remitting multiple sclerosis (RRMS) to test a lower dose of IMU-838, its leading oral experimental therapy, in its ongoing Phase 2 EMPhASIS trial. The decision was based on previous trial results showing that both doses tested (30 and 45 mg…

The Israeli Innovation Authority has awarded Owlytics Healthcare a $1.3-million grant to support the company’s development of wearable artificial intelligence (AI) technology that has the potential to improve multiple sclerosis (MS) therapies and better evaluate treatment efficacy in clinical studies. The device would be able to continuously…

An autologous hematopoietic stem cell transplant (AHSCT) is more effective than Lemtrada (alemtuzumab) at achieving no evidence of disease activity and preventing relapses in people with relapsing-remitting multiple sclerosis (RRMS), a real-life study in Sweden reported. Adverse events (side effects) were more frequent with AHSCT over the first three…

Treatment with Tysabri (natalizumab) was more effective than Gilenya (fingolimod) in helping people with relapsing–remitting multiple sclerosis (RRMS) achieve no evidence of disease activity, a head-to-head study suggested. The study, “BEST-MS: A prospective head-to-head comparative study of natalizumab and fingolimod in active relapsing MS,” was…

The brain volume of people with relapsing-remitting multiple sclerosis (RRMS) undergoes a dynamic cycle of enlargement and contractions, a new study shows. Patients with a lower volume (contractions) had less severe MS and a shorter disease duration, the study found. Overall, these findings suggest that frequent monitoring of the…

The use of disease-modifying therapies (DMTs) in adults with multiple sclerosis (MS) increased the risk of precancerous growth in those older than 45 years of age, according to an age-related adverse events analysis of several dozen clinical trials. …

Extracellular vesicles (EVs), tiny sacs released from myelin-producing cells called oligodendrocytes, may help dampen the immune system’s attack against myelin, whose loss is the hallmark of multiple sclerosis (MS), a new mouse study shows. The findings suggest that oligodendrocytes-released EVs could work as an universal immunotherapy for MS…

Adults with active relapsing-remitting multiple sclerosis (RRMS) treated with Tysabri (natalizumab) had fewer new and accumulated lesions, and a lower relapse rate than those treated with Gilenya (fingolimod) for 24 weeks, according to…

A Phase 3 trial is underway in the U.S. to assess the safety and efficacy of Sativex (nabiximols), an oral spray that contains cannabis extracts, in treating spasticity — muscle stiffness or spasms — associated with multiple sclerosis (MS). Sativex, by…

Using a two-pronged approach, researchers were able to restore myelin on regenerated nerve fibers in a mouse model of optic nerve injury, which has implications for multiple sclerosis (MS) and other diseases associated with myelin loss, a study reported. The study, “…

A $25,000 contest is inviting entrepreneurs who have multiple sclerosis (MS), or take care of someone with MS, to pitch their non-therapeutic solutions for people with the neurodegenerative disorder. The virtual Innovation Challenge, which takes place in March 2021, is part of a collaboration between patient-powered platform Lyfebulb…

A small protein isolated from beetroot is able to block the activity of an enzyme called prolyl oligopeptidase (POP), which breaks down certain hormones and signaling molecules, and is thought to control the body’s inflammatory responses. According to the researchers, the discovery of this plant-derived protein may make possible…

InnoCare Pharma is preparing to launch a Phase 2 trial to assess the safety and efficacy of orelabrutinib, its investigational Bruton tyrosine kinase inhibitor, in patients with relapsing-remitting multiple sclerosis (RRMS). The trial, which is expected to enroll approximately 160 patients, will be carried out in the U.S.

Genentech’s Ocrevus (ocrelizumab) continues to be the most prescribed treatment for people with progressive forms of multiple sclerosis (MS) among U.S. neurologists, according to the latest Spherix Global Insights’ report. However, Novartis’ Mayzent (siponimod) “is beginning to close the gap” with Ocrevus among those with active secondary progressive MS…

People with multiple sclerosis (MS) are invited to submit their artwork to the Multiple Sclerosis Association of America‘s (MSAA) annual Art Showcase. The online event aims to share the work of artists with MS and their life stories. Applications are opened till Dec. 14 and are restricted to…

There may be a better way of repairing the insulation surrounding damaged neurons that could lead to new treatments for multiple sclerosis (MS), a study suggests. The data showed that blocking the protein sphingomyelin hydrolase neutral sphingomyelinase 2, or nSMase2, could improve the quality of the myelin surrounding…

Adults with multiple sclerosis (MS) and other neurological disorders are being recruited to take part in a 12-week clinical trial that aims to assess the health benefits of home-based tele-exercise — performed while seated — led by the Burke Neurological Institute, in New York, according to an…